Genentech's capacity expansion options to meet growing demand for cancer drug Avastin

[object Object],[object Object],[object Object],[object Object],[object Object],Introduction to case Outline

[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Slide Conclusion

Introduction to Case ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Slide

Most Admired Biotech Company

Background Slide ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

1AVASTIN : drug for patients with previously untreated metastatic cancer of the colon or rectum Slide Overview Mission To be the leading biotechnology company, using human genetic information to discover, develop, manufacture and commercialize biotherapeutics that address significant unmet medical needs. In 2003 Revenues : $3,300 million 79 % from product sales Net Income: $563 million In 2004 AVASTIN 1 was approved by FDA First nine months of 2004 sales of AVASTIN 15 % or $2,684,000 million TARCEVA & OMNITARG both drugs that Genentech promise to launch in the next year

Genentech Product Information (2001-2003) Slide ($ in millions)

Organization ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Slide In 2004 Product Operation Product development Part in

Ebersman ,[object Object],[object Object],[object Object],Slide

Manufacturing Process ,[object Object],Slide To created drugs based on recombinant DNA (inserting DNA into cells to produce protein) Operation Locations Vacaville (CA ) Porri ño Spain

Manufacturing Process Flow Chart (per Batch) Slide 2,000L 12,000L ( 0.75gm/L )

Slide Ultra Filtration Frozen Bulk Packaged Products

Opportunities & Challenges ,[object Object],Slide ,[object Object],[object Object],[object Object]

[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Capacity Overview Slide In 2000 FDA approved for CCP1 In 2004 CCP1 became a Genentech’s high volume drugs (Rituxan , Herceptin , Xolair and Avastin Capacity : 12 12,000liter production vessels

Vacaville Expansion ,[object Object],Slide >>In developing CCP2 , - double capacity in each line (build eight 25,000 liter production vessels) - without higher expenditure Capacity : 8 25,000liter production vessels

Contract Manufacturing Relationships ,[object Object],Slide

[object Object],Slide ,[object Object],[object Object],[object Object]

[object Object],[object Object],[object Object],[object Object],Potential Market Size Slide

A model for all cancer indication Slide

Slide Capacity Planning Demand-upside Demand-Basecase Demand- Downside Sample Capacity Requirements Chart

Slide Plan Economic optimum a Total Product Demand (kilograms) Distribution of Possible Demand Scenerios

Capacity Expansion Options ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Slide

[object Object],[object Object],[object Object],[object Object],Location Slide

Genentech's capacity expansion options to meet growing demand for cancer drug Avastin

Empfohlen

Empfohlen

Weitere ähnliche Inhalte

Was ist angesagt?

Was ist angesagt? (15)

Ähnlich wie Genentech's capacity expansion options to meet growing demand for cancer drug Avastin

Ähnlich wie Genentech's capacity expansion options to meet growing demand for cancer drug Avastin (20)

Kürzlich hochgeladen

Kürzlich hochgeladen (20)

Genentech's capacity expansion options to meet growing demand for cancer drug Avastin